Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TAK
stocks logo

TAK

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
1.15T
-4.6%
--
--
1.16T
-1.11%
--
--
1.93T
+69.07%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Takeda Pharmaceutical Company Limited (TAK) for FY2026, with the revenue forecasts being adjusted by 0.28% over the past three months. During the same period, the stock price has changed by -1.91%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.28%
In Past 3 Month
Stock Price
Go Down
down Image
-1.91%
In Past 3 Month
1 Analyst Rating
up Image0
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image0
Current: 14.890
sliders
Low
16.00
Averages
16.00
High
16.00
up Image0
Current: 14.890
sliders
Low
16.00
Averages
16.00
High
16.00
Needham
Needham
Buy
maintain
$270 -> $300
2025-05-29
Reason
Needham
Needham
Price Target
$270 -> $300
2025-05-29
maintain
Buy
Reason
Needham raised the firm's price target on Veeva (VEEV) to $300 from $270 and keeps a Buy rating on the shares after its Q1 earnings beat and guidance raise. Despite concerns related to Salesforce's (CRM) recent announcement of winning Takeda (TAK) for CRM, Veeva is executing well on the conversion to Vault, with over 200 customers expected to be live by company's summit next spring, the analyst tells investors in a research note. Veeva also believes that custom builds for companies like Takeda may prove too costly, leading the company to see opportunities for competitive win backs, the firm added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK.N) is 27.43, compared to its 5-year average forward P/E of 28.26. For a more detailed relative valuation and DCF analysis to assess Takeda Pharmaceutical Co Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
28.26
Current PE
27.43
Overvalued PE
40.71
Undervalued PE
15.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
9.39
Current EV/EBITDA
9.17
Overvalued EV/EBITDA
10.55
Undervalued EV/EBITDA
8.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.62
Current PS
1.48
Overvalued PS
1.78
Undervalued PS
1.45

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

TAK News & Events

Events Timeline

(ET)
2025-06-03
10:14:18
Takeda reports EC approves Adcetris combination for Hodgkin lymphoma
select
2025-06-01 (ET)
2025-06-01
16:01:08
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
select
2025-05-19 (ET)
2025-05-19
16:15:41
Veeva has 'meaningful' Life Science head start over Salesforce, says Oppenheimer
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-03Newsfilter
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

  • Approval of ADCETRIS: The European Commission has approved ADCETRIS (brentuximab vedotin) in combination with a chemotherapy regimen for adult patients with newly diagnosed Stage IIb/III/IV Hodgkin lymphoma, based on positive results from the Phase 3 HD21 trial demonstrating superior safety and efficacy compared to the standard treatment eBEACOPP.

  • Expanded Treatment Options: This approval marks the second indication for ADCETRIS in frontline Hodgkin lymphoma, enhancing its therapeutic reach within the European Union, where it is already approved for six other distinct indications.

Preview
9.0
06-03SeekingAlpha
Takeda, Pfizer's Adcetrix wins EU approval for hodgkin lymphoma

  • Approval of Adcetris: The European Commission has approved Pfizer and Takeda's antibody-drug conjugate, Adcetrix, for use in combination with chemotherapy for adults with newly diagnosed stage IIb Hodgkin lymphoma, following a positive opinion from the EU drug regulator.

  • Distribution Rights: Takeda is responsible for the worldwide distribution of Adcetris, except in the US and Canada where Pfizer holds commercialization rights; this marks the second approval for an ADCETRIS-based regimen for frontline Hodgkin lymphoma in the EU.

Preview
1.0
05-27Newsfilter
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

  • Innovators in Science Award Announcement: Takeda has opened applications for its Innovators in Science Award, which recognizes early-career scientists in gastrointestinal and inflammatory diseases, neuroscience, and oncology, offering a total of $250,000 in prizes and a 12-month career development program.

  • Commitment to Scientific Excellence: The award aims to support emerging biomedical researchers by providing funding, mentorship, and collaboration opportunities, reinforcing Takeda's dedication to fostering innovation and scientific discovery.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK) stock price today?

The current price of TAK is 14.89 USD — it has decreased -1.19 % in the last trading day.

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK)'s business?

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

arrow icon

What is the price predicton of TAK Stock?

Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK)'s revenue for the last quarter?

Takeda Pharmaceutical Co Ltd revenue for the last quarter amounts to 1.05T USD, increased 0.24 % YoY.

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK)'s earnings per share (EPS) for the last quarter?

Takeda Pharmaceutical Co Ltd. EPS for the last quarter amounts to -65.31 USD, increased 3301.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for Takeda Pharmaceutical Co Ltd (TAK)'s fundamentals?

The market is revising Upward the revenue expectations for Takeda Pharmaceutical Company Limited (TAK) for FY2026, with the revenue forecasts being adjusted by 0.28% over the past three months. During the same period, the stock price has changed by -1.91%.
arrow icon

How many employees does Takeda Pharmaceutical Co Ltd (TAK). have?

Takeda Pharmaceutical Co Ltd (TAK) has 49281 emplpoyees as of June 18 2025.

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK) market cap?

Today TAK has the market capitalization of 46.51B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free